Trim32 is an E3-ubiquitin ligase and a member of a family of scaffold proteins involved in both cancer and human development. We made the novel association of Trim32 activation with cancer through carcinogenesis studies in mouse keratinocyte models and have preliminarily confirmed this association in human squamous cell carcinoma (SCC). We have identified Piasy as a substrate protein targeted for degradation by Trim32 ubiquitylation, providing the first evidence for how Piasy is regulated in cells. Others have established that Piasy is a pro-apoptotic E3-SUMO ligase involved in regulation of tumor suppressor p53 and of NFkB cellular survival pathways. Piasy's role in cancer is evident as it is targeted for inactivation by the high-risk HPV-E6 protein implicated in human cervical carcinoma, and its downregulation is prognostic for conversion from myelodysplastic syndrome (MDS) to later stages and chronic myeloid leukemia (CML). Piasy is a pro- apoptotic factor, inducing apoptosis in CML cells, human fibroblasts and mouse keratinocytes. We show that Trim32 protects keratinocytes from apoptosis induced by UVB and synergized by TNFa. Moreover, we find an inverse correlation between Piasy and Trim32 expression levels in human SCC. These data suggest a direct role of Trim32 activation and Piasy degradation in epithelial carcinogenesis and tumor progression. We propose to define Trim32/Piasy interactions in intracellular signaling, carcinogenesis and human SCC according to the following aims: 1) define the dynamic regulation of Piasy subcellular localization by the Trim32 E3 ligase scaffold protein and the role of these interactions in survival pathways in epidermal keratinocytes;2) examine the role of Trim32 and Piasy in initiation, promotion and malignant progression in keratinocytes during epidermal carcinogenesis;3) explore the predictive value of Trim32/Piasy status in human skin and head and neck SCC prognosis as a basis for future strategies for molecular targeting of Trim32/Piasy interactions or downstream effectors in cancer. The expression of Trim32 and Piasy beyond epithelia, such as in hematologic, muscle and neurological tissues and the presence of Trim32 inactivating mutations in two human hereditary syndromes imply broader significance of understanding Trim32 and Piasy regulation in human disease. PROJECT NARRATIVE Trim32 and Piasy: Two enzymes with opposing roles in cancer development Trim32 is a ?scaffold? protein that controls the timing and location of other proteins that must interact appropriately to cause normal tissue development and that, if abnormal, can lead to cancer. We have shown that Trim32 adds a small molecule ?ubiquitin? and destroys Piasy (an enzyme that is needed for tumor suppression and cell survival mediated by important gene regulators p53, NFB, STAT and Smad/TGFbeta), providing the first evidence for how Piasy is regulated in cells. Understanding how the very earliest changes detectable in cancer, such as Trim32 activation, extend abnormal cell survival and promote further changes (activation of cancer genes and inactivation of tumor suppressor genes) provides a basis for novel selective, less toxic molecular-targeted prevention and therapy of skin cancers and perhaps cancers from other tissues where Trim32 and Piasy are expressed, such as chronic myelogenous leukemia, muscle and brain tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098577-09
Application #
8214969
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Okano, Paul
Project Start
2003-05-15
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2014-01-31
Support Year
9
Fiscal Year
2012
Total Cost
$334,297
Indirect Cost
$117,221
Name
Oregon Health and Science University
Department
Dermatology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Liu, Yuangang; Bridges, Rebecca; Wortham, Aaron et al. (2012) NF-?B repression by PIAS3 mediated RelA SUMOylation. PLoS One 7:e37636
Phillips, Kevin G; Wang, Yun; Levitz, David et al. (2011) Dermal reflectivity determined by optical coherence tomography is an indicator of epidermal hyperplasia and dermal edema within inflamed skin. J Biomed Opt 16:040503
Weber, Stephen M; Bornstein, Sophia; Li, Yuexin et al. (2011) Tobacco-specific carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induces AKT activation in head and neck epithelia. Int J Oncol 39:1193-8
Christiano, Angela; Kulesz-Martin, Molly; Bickenbach, Jackie R (2010) Montagna Symposium 2009: Genetic-epigenetic Basis of Skin Diseases. J Invest Dermatol 130:1199-201
Liu, Yuangang; Lagowski, James P; Gao, Shangpu et al. (2010) Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Invest Dermatol 130:1384-90
Johnson, J; Lagowski, J; Lawson, S et al. (2008) p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis. Oncogene 27:2780-7
Johnson, Jodi; Lagowski, James; Sundberg, Alexandra et al. (2007) p73 loss triggers conversion to squamous cell carcinoma reversible upon reconstitution with TAp73alpha. Cancer Res 67:7723-30
Albor, Amador; El-Hizawi, Sally; Horn, Elizabeth J et al. (2006) The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NFkappaB. J Biol Chem 281:25850-66
Johnson, Jodi; Lagowski, James; Sundberg, Alexandra et al. (2005) P53 family activities in development and cancer: relationship to melanocyte and keratinocyte carcinogenesis. J Invest Dermatol 125:857-64
Schneider, Brandt L; Kulesz-Martin, Molly (2004) Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 25:2033-44